CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Parallel Bio›
Library
Parallel Bio

Parallel Bio

Parallel Bio uses human immune organoids and computational tools to support drug discovery and therapy testing.

Brisbane, CA, US🇺🇸
Founded
2021
Accelerator
Y Combinator logoY CombinatorS21
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Parallel Bio - Library

parallel.bio·Crawled Sep 27, 2026·

Topics

Publication type

Content origin
Row density

Blog

1 page
  1. blog/

    The official knowledge center of Parallel Bio.

Careers & Hiring

1 page
  1. Careers/careers

About

1 page
  1. About/about

Contact

1 page
  1. Connect/contact

Homepage

2 pages
  1. Homepage/

    Parallel Bio reimagined the entire drug discovery process from the ground up - creating a system that charts the map of human biology. A system that’s population-scale, perturbable, and fully human - with the power to reveal the biological landscape of any disease.

  2. Homepage/

    Parallel Bio reimagined the entire drug discovery process from the ground up - creating a system that charts the map of human biology. A system that’s population-scale, perturbable, and fully human - with the power to reveal the biological landscape of any disease.

Privacy

1 page
  1. Privacy Policy/privacy-policy

    Thank you for visiting https://www.parallel.bio (the “Site”), owned and operated by Parallel Biosystems, Inc. (“we,” or “us”). We respect your privacy and, whether you are visiting the Site as a job applicant, customer, or member of the general public, you are entitled to the protection of your personal information. Please read this Privacy Policy to learn how we treat your personal information.

Coverage

5 items
  1. Parallel Bio Establishes San Francisco Bay Area as U.S. Headquarters, Appoints Five Industry Leaders to Advisory Boardbusinesswire.com/news/home/20260616363147/en/Parallel-Bio-Establishes-San-Francisco-Bay-Area-as-U.S.-Headquarters-Appoints-Five-Industry-Leaders-to-Advisory-Board

    Parallel Bio establishes the San Francisco Bay Area as its U.S. headquarters and appoints five industry leaders to its advisory board.

    Jun 2026 · Business WireNews article

  2. Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discoverybusinesswire.com/news/home/20250612697548/en/Parallel-Bio-Secures-%2421-Million-in-Series-A-to-Advance-Human-First-Drug-Discovery

    Parallel Bio raises $21 million in Series A funding led by AIX Ventures to expand its human-first drug discovery platform. The company says the financing will support expansion of its platform for human-first drug discovery, with AIX Ventures leading the Series A round.

    Jun 2025 · Business WireNews article

  3. Parallel Bio Launches Clinical Trial in a Dish to Speed Drug Discoverybusinesswire.com/news/home/20240516952454/en/Parallel-Bio-Launches-Clinical-Trial-in-a-Dish-to-Speed-Drug-Discovery

    Parallel Bio launches Clinical Trial in a Dish, with five pharmaceutical companies testing twenty drug candidates.

    May 2024 · Business WireNews article

  4. Parallel Bio Expands Scientific Leadership and Advisors from GSK, MIT, and Stanfordbusinesswire.com/news/home/20230119005288/en/Parallel-Bio-Expands-Scientific-Leadership-and-Advisors-from-GSK-MIT-and-Stanford

    Parallel Bio appoints Dwight Morrow as vice president and head of platform, and adds Darrell Irvine and Nima Aghaeepour as scientific advisors. The company describes the additions as coming from GSK, MIT, and Stanford.

    Jan 2023 · Business WireNews article